Trademarkia Logo

Canada

C$
STARS DESIGN
REGISTERED

on 8 Sept 2021

Last Applicant/ Owned by

ASTELLAS PHARMA INC.

5-1, Nihonbashi-Honcho 2-chome,Chuo-kuTokyo 103-8411

JP

Serial Number

2016946 filed on 31st Oct 2019

Registration Number

TMA1108786 registered on 8th Sept 2021

Registration expiry Date

31st Oct 2029

Correspondent Address

BAKER & MCKENZIE LLP

BROOKFIELD PLACE181 BAY STREET, SUITE 2100P.O. BOX 874TORONTO

ONTARIO

CA

M5J2T3

STARS DESIGN

Trademark usage description

pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of central nervo Read More

Vienna Information


1 . 1 . 10

Stars with more than four pointsÉtoiles à plus de quatre pointes

1 . 1 . 1

StarsÉtoiles

1 . 1 . 2

One starUne étoile

1 . 1 . 12

Stars with uneven points -- Note: Including sparks consisting of uneven-pointed stars.Étoiles à pointes irrégulières -- Note: Y compris les étincelles constituées d'étoiles à pointes irrégulières.

1 . 1 . 14

Incomplete starsÉtoiles incomplètes

24 . 15 . 21

Arrowheads -- Note: Not including arrowheads in the form of angles (26.3.23).Pointes de flèches -- Note: Non compris les pointes de flèches en forme d'angles (26.3.23).

26 . 3 . 1

One triangleUn triangle

26 . 3 . 6

Triangular figures with one or more convex or concave sidesFigures triangulaires à un ou plusieurs côtés convexes ou concaves

Classification Information


Class [005]
Pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of genetic diseases and disorders, namely, enzyme deficiency; pharmaceutical preparations for the treatment of immunological diseases and disorders, namely, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases and disorders, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of menopausal diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of musculoskeletal diseases and disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of neurological diseases and disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of peripheral nervous system diseases and disorders, namely, convulsions and seizures; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of renal, respiratory, urogenital, urological, osteopathic, hematological and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of viral diseases and disorders, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for the treatment of pain and diabetes; pharmaceutical preparations for use in regenerative medicine, namely the use of platelet rich plasma stem cells and scaffolds for the treatment of injuries and degeneration of joints; pharmaceutical preparations, namely, antibacterial preparations, antifungal preparations, antiviral preparations, dermatological preparations, immunosuppressants, and tissue repair preparations; human vaccines.


Classification kind code

11

Mark Details


Serial Number

2016946

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 222
on 14th Jun 2021
Opposition Start Date Notice Sent
Submitted for opposition 26
on 24th May 2021
Approved
Submitted for opposition 27
on 24th May 2021
Approval Notice Sent
Submitted for opposition 22
on 18th May 2021
Search Recorded
Submitted for opposition 256
on 12th Jan 2021
Notification of Possible Opposition Sent
Submitted for opposition 257
on 12th Mar 2020
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 12th Mar 2020
Created
Submitted for opposition 31
on 12th Mar 2020
Formalized
Submitted for opposition 228
on 31st Oct 2019
International Registration
Submitted for opposition 30
on 31st Oct 2019
Filed